FLEX
FLEX to Buy EPC Power in $4.4 Billion Stock Purchase Deal
Flex unit ACS Acquisitions agreed to buy all shares of inverter maker EPC Power Corp. from Charge Parent for $4.4 billion, with Flex guaranteeing the deal.
News from SEC filings, FDA decisions and company releases, drafted with AI and checked by an editor before publication. How we work: redfiled.com/how-we-work/
FLEX
Flex unit ACS Acquisitions agreed to buy all shares of inverter maker EPC Power Corp. from Charge Parent for $4.4 billion, with Flex guaranteeing the deal.
IONS
Ionis wins first-ever approval for a disease-modifying Alexander disease therapy, plus a rare pediatric disease priority review voucher.
NLST
The Federal Circuit affirmed PTAB rulings invalidating claims of five Netlist memory patents challenged by Micron, including one precedential decision.
PSNY
The EV maker cut its net loss by 29% in H1 2026, but adjusted EBITDA worsened to a loss of $521 million while deliveries were roughly flat.
CPB
Q4 adjusted EPS fell 37% to $0.39, the quarterly payout drops to $0.25, and Campbell's targets $500 million in cost savings by fiscal 2030.
CIEN
Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.
APGE
An 8-K filing shows Apogee Therapeutics has completed a change-of-control transaction, replaced its board and recapitalized to just 1,000 shares.
ESTC
Elastic's CTO and co-founder disposed of about 476,000 ordinary shares between August 31 and September 2, cutting his stake to roughly 1.58 million shares.
AUGO
A Form 4 shows director Bruno Sousa Mauad sold 127,500 Aura Minerals shares at $81.20 apiece on Aug. 31, cutting his stake by more than 40%.
CRWD
Two CrowdStrike insiders sold a combined 40,000 Class A shares on Aug. 31 and Sept. 1 at prices between roughly $213 and $234.
NESR
National Energy Services Reunited's chief executive sold 100,000 ordinary shares at $35.00 and transferred another 675,000 shares as a gift.
RVMD
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.